123 Possible Factors Affecting Efficacy of Dapoxetine 30mg Treatment in Chinese Patients With Premature Ejaculation

Abstract

Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor (SSRI) and it is the first drug approved in China for on-demand treatment of premature ejaculation (PE). An integrated analysis of 5 Phase III trials showed that >60% of patients treated with dapoxetine reported that their PE was at least “slightly better”. However, the effect of dapoxetine on Chinese patients with PE has been seldom reported. The aim of this study was to evaluate the effect of treatment with dapoxetine 30 mg on-demand on Chinese patients with PE. Possible factors that may affect dapoxetine treatment efficacy were also investigated. This retrospective, open, observational study included 172 patients with PE. The patients were assessed using a detailed medical, sexual and PE treatment history. Patients received dapoxetine therapy (30 mg on-demand) for 4 weeks, and then followed in outpatient clinic visits or by telephone. Data on premature ejaculation diagnostic tool (PEDT), self-reported intravaginal ejaculatory latency time (IELT), intromission frequency, premature ejaculation profile (PEP), and clinical global impression of change (CGIC) were recorded. Patients were divided into “CGIC=0” and “CGIC≥1” accordingly. Baseline clinical data were compared between these 2 groups to determine possible factors that may affect dapoxetine treatment effectiveness.